Two studies highlight advances in Parkinson’s research: one identifies perivascular fluid diffusivity as an early clinical progression biomarker using advanced MRI, enabling prognosis prior to major motor symptom onset; another employs integrative multi-omics to repurpose meclofenoxate hydrochloride for Parkinson’s treatment, tapping into its memory-enhancing potential. These provide promising avenues for earlier intervention and therapeutic development.